<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-148550" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Asthma and COPD Overlap</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Awad</surname>
            <given-names>Mohammed T.</given-names>
          </name>
          <aff>Wayne State University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sankari</surname>
            <given-names>Abdulghani</given-names>
          </name>
          <aff>Wayne State University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mohammed Awad declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abdulghani Sankari declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>11</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-148550.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Asthma and chronic obstructive pulmonary disease (COPD) are the most common obstructive lung diseases observed during clinical practice. They have common characteristics and similar clinical presentation. Moreover, they usually have the same presentation on pulmonary function tests (PFT). Asthma and COPD overlap is a term to describe the patients who present with both asthma and COPD symptoms. This activity illustrates the clinical characteristics, diagnosis, and treatment of asthma-COPD overlap.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Summarize the epidemiology of asthma-COPD overlap (ACO).</p></list-item><list-item><p>Explain the common physical exam findings associated with ACO.</p></list-item><list-item><p>Identify the typical presentation of a patient with ACO.</p></list-item><list-item><p>Differentiate treatment options between ACO and asthma or COPD alone.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=148550&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=148550">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-148550.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Asthma and chronic obstructive pulmonary disease (COPD) are the most common obstructive lung diseases observed during clinical practice. They have common characteristics and&#x000a0;similar&#x000a0;clinical presentation. Moreover, they usually have the same presentation on pulmonary function tests (PFT). Therefore, the term "asthma-COPD overlap" (ACO) was used to describe the cases in that they have both features of asthma and COPD. Gibson first described ACO in 2009.<xref ref-type="bibr" rid="article-148550.r1">[1]</xref>&#x000a0;&#x000a0;</p>
        <p>ACO is defined as an obstructive lung condition with clinical and inflammatory&#x000a0;characteristics&#x000a0;of asthma and COPD or predominantly COPD&#x000a0;combined with&#x000a0;bronchodilator responsiveness and elevated peripheral eosinophils count. Although the condition has now started to be described more, the last Global Initiative for Chronic Obstructive Lung Disease (GOLD) did not use ACO as a distinct condition, given there is no universally accepted definition.<xref ref-type="bibr" rid="article-148550.r2">[2]</xref>&#x000a0;</p>
        <p>The definition used commonly for ACO is the presence of&#x000a0;airflow obstruction in individuals with a history of asthma and older than 40.<xref ref-type="bibr" rid="article-148550.r3">[3]</xref> According to the Global Initiative for Asthma (GINA) and GOLD, patients usually have chronic airway disease symptoms with cough, wheezing, recurrent lower respiratory tract infection, and asthma and COPD features.&#x000a0;<xref ref-type="bibr" rid="article-148550.r2">[2]</xref>&#x000a0;This review will describe the clinical presentation, evaluation, and management of patients with ACO.</p>
      </sec>
      <sec id="article-148550.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>There is no distinct cause for ACO but rather a continuum phenomenon for airflow obstruction&#x000a0;between asthma and COPD. The causes are usually a combination of both COPD and asthma causes. This includes cigarette smoking and environmental factors. Most epidemiologic studies show that tobacco use is the most significant risk factor for COPD. For instance, a retrospective cohort study (n = 8045) discovered that subjects who smoked cigarettes for the entire 25-year observation period had a higher risk of developing COPD than non-smokers (36 versus 8%).<xref ref-type="bibr" rid="article-148550.r4">[4]</xref>&#x000a0;</p>
        <p>Increased airway responsiveness to&#x000a0;allergens or other external triggers is a risk factor for asthma and COPD. A retrospective cohort study (n = 9651) found that individuals with increased airway responsiveness had a higher incidence of COPD over 11 years.<xref ref-type="bibr" rid="article-148550.r5">[5]</xref>&#x000a0;Asthma and atopy are also considered risk factors for COPD development, leading to the development of ACO. An observational study of 1025 men (mean age 61 years)&#x000a0;showed that atopy increases COPD risk.<xref ref-type="bibr" rid="article-148550.r6">[6]</xref></p>
      </sec>
      <sec id="article-148550.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Since there is&#x000a0;no exact definition of ACO, it is difficult to estimate the epidemiology of the disease. However, some estimates from self-reported&#x000a0;physician diagnoses and a combination of PFTs and clinical presentations showed that the prevalence is 2 to 3%.<xref ref-type="bibr" rid="article-148550.r3">[3]</xref>&#x000a0;Compared to COPD and asthma alone, the prevalence of ACO&#x000a0;tends to be higher; 2 to 12% and 5 to 17%, respectively. In the United States, the ACO prevalence estimate is 3.7%. In China, the prevalence is estimated at around 0.61%.<xref ref-type="bibr" rid="article-148550.r7">[7]</xref><xref ref-type="bibr" rid="article-148550.r8">[8]</xref>&#x000a0;</p>
        <p>To determine the exact epidemiology of the disease, we need first to establish a clear definition. In a population with asthma or COPD alone, it is estimated that up to a third have ACO (10 to 30% and 25%, respectively).<xref ref-type="bibr" rid="article-148550.r9">[9]</xref>&#x000a0;ACO is more predominant in women and those who have obesity.<xref ref-type="bibr" rid="article-148550.r9">[9]</xref></p>
        <p>Studies also showed a higher incidence of ACO among&#x000a0;those with lower education and socioeconomic status than those with COPD alone.<xref ref-type="bibr" rid="article-148550.r10">[10]</xref><xref ref-type="bibr" rid="article-148550.r11">[11]</xref>&#x000a0;Patients with ACO tend to have a less controlled disease burden concerning exacerbation rates and clinical symptoms than patients with either asthma or COPD alone.<xref ref-type="bibr" rid="article-148550.r12">[12]</xref><xref ref-type="bibr" rid="article-148550.r13">[13]</xref></p>
      </sec>
      <sec id="article-148550.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Asthma and COPD are diseases that result due to different pathogeneses. However, two published explanations discussed the mechanism of ACO. The Dutch hypothesis was published in the 1960s by&#x000a0;Dick Orie. He suggested that asthma and COPD have the same genetic factors&#x000a0;but different&#x000a0;environmental factors that can present with different phenotypes. In ACO, the patient will have features of both diseases due to exposure to both environmental factors, and they cannot be separated.</p>
        <p>On the other hand, the British hypothesis, first proposed in 1965, suggested that ACO pathophysiology has features of both COPD and asthma. However, risk factors such as smoking contribute to asthma, and asthma-related factors, such as allergies, contribute to COPD.<xref ref-type="bibr" rid="article-148550.r14">[14]</xref>&#x000a0;Likewise,&#x000a0;exposure to toxic particles or gases (such as tobacco smoking and indoor biomass fuel use) plays a vital role in the pathophysiology of ACO.<xref ref-type="bibr" rid="article-148550.r3">[3]</xref></p>
      </sec>
      <sec id="article-148550.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Patients with ACO usually have the same asthma and COPD symptoms, including cough, sputum production, shortness of breath, and wheezing. However, exacerbation rates were&#x000a0;4 to 5 times higher in ACO patients compared with those with asthma or COPD alone.<xref ref-type="bibr" rid="article-148550.r15">[15]</xref>&#x000a0;Also, it was found that patients with ACO have more emergency department visits and hospital admission.<xref ref-type="bibr" rid="article-148550.r10">[10]</xref></p>
        <p>The physical examination&#x000a0;findings include wheezing and hyperinflation signs, the same as in&#x000a0;chronic obstructive lung disease findings. However,&#x000a0;findings can be normal, with periodic exacerbations in between.<xref ref-type="bibr" rid="article-148550.r16">[16]</xref></p>
      </sec>
      <sec id="article-148550.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The first step&#x000a0;in evaluating&#x000a0;suspected ACO is the pulmonary function test (PFT) with FEV1 level reflecting disease severity. Spirometry in ACO should show a postbronchodilator FEV1/FVC of less than 0.70. Patients with ACO typically exhibit a bronchodilator response, which is defined as an increase in forced expiratory volume in one second (FEV1) or forced vital capacity (FVC) after bronchodilation of more than 10% of predicted value; however, asthma is associated with a more significant increase in FEV1 or FVC of more than 15% of the predicted value. In individuals with ACO, postbronchodilator FEV1 and FEV1/FVC typically stay abnormally low, while a normal postbronchodilator, FEV1, and FVC&#x000a0;are more consistent with asthma.&#x000a0;</p>
        <p>There are multiple criteria for ACO diagnosis. In 2016, a global expert panel share that patients must meet all&#x000a0;3 main and at least one minor criterion to be diagnosed with ACO. The main criteria are as follows:</p>
        <p>The patients should be at least 40 years old with chronic airflow&#x000a0;obstruction (post-bronchodilator FEV1/FVC 0.70 or the lower limit of normal)</p>
        <p>They have at least 10 pack-years of tobacco use</p>
        <p>They have a history of asthma before age 40 or more than 400&#x000a0;milliliters (mL) increase in FEV1 after bronchodilator use.&#x000a0;</p>
        <p>A documented history of atopy or allergic rhinitis, a bronchodilator response in FEV1 of at least 200&#x000a0;ml and 12% from baseline values during two or more visits, or a peripheral blood eosinophil count of at least 200 cells/mL are the minor criteria. The Global Initiative for Asthma (GINA) posted the same categories to support the diagnosis of ACO. A reduced diffusion capacity is not consistent with asthma but could be seen more often in individuals with COPD.</p>
        <p>Other workups&#x000a0;should include peripheral eosinophils count, immunoglobulin E level, and respiratory allergen panel.<xref ref-type="bibr" rid="article-148550.r17">[17]</xref>&#x000a0;An elevated IgE of more than 100&#x000a0;international units/mL or peripheral eosinophil level of more than 200&#x000a0;cells/microL suggests ACO or asthma.&#x000a0;</p>
        <p>When evaluating dyspnea, a chest radiograph is usually taken. Chest radiographs may reveal hyperinflation in ACO patients, but they often cannot distinguish between asthma, COPD, and ACO.<xref ref-type="bibr" rid="article-148550.r18">[18]</xref></p>
      </sec>
      <sec id="article-148550.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>ACO management is mainly divided into two categories: nonpharmacological and pharmacological. Nonpharmacological measures include smoking cessation, which helps reduce the rate of&#x000a0; FEV1 decline.<xref ref-type="bibr" rid="article-148550.r19">[19]</xref>&#x000a0;Also, avoidance of exposure to other sources of smoke can be helpful. Since infections are one of the leading causes of exacerbation of asthma and COPD, getting the appropriate vaccines will help to reduce those exacerbations. This includes yearly influenza vaccine and pneumonia vaccines. Other interventions include education about proper inhaler technique and referral to pulmonary rehabilitation.<xref ref-type="bibr" rid="article-148550.r20">[20]</xref></p>
        <p>Regarding pharmacological&#x000a0;interventions, inhaled corticosteroids (ICS) and bronchodilators continue to be the mainstay of treatment for most patients with ACO, much like asthma and COPD. Choosing the best bronchodilator medication for these patients is still uncertain, though. In its most recent edition, the Global Initiative for Asthma (GINA) and the Global Initiative for Obstructive lung disease&#x000a0;&#x000a0;(GOLD) advise starting asthma therapy after being diagnosed with ACO. This is justified by ICS's crucial role in treating patients with asthma-like symptoms. However, formal data are scarce because ACO patients have always been excluded from clinical studies of asthma and COPD drugs.<xref ref-type="bibr" rid="article-148550.r16">[16]</xref>&#x000a0;</p>
        <p>For as-needed symptom alleviation, all ACO patients should have prompt access to an inhaled bronchodilator with a quick start of action (such as a short-acting beta agonist, short-acting muscarinic antagonist, or combination). Also, avoiding treatment with Long-Acting Beta-Agonists (LABA) alone (LABA monotherapy) without ICS in patients with asthma symptoms is a crucial component of ACO management.<xref ref-type="bibr" rid="article-148550.r21">[21]</xref>&#x000a0;Additionally, mounting data points to a connection between higher blood eosinophil levels and ICS responsiveness in COPD.<xref ref-type="bibr" rid="article-148550.r22">[22]</xref><xref ref-type="bibr" rid="article-148550.r23">[23]</xref>&#x000a0;</p>
        <p>LABA monotherapy&#x000a0;should be&#x000a0;avoided in asthma, according to findings from the Salmeterol Multicenter Asthma Research Trial (SMART).<xref ref-type="bibr" rid="article-148550.r24">[24]</xref>&#x000a0;Salmeterol was delivered using a metered-dose inhaler in the SMART study, a 28-week randomized trial, compared to a placebo. A rise in respiratory- and asthma-related mortality, notably in African American patients, was discovered in an interim review of 26,355 patients. Therefore, LABA monotherapy should be avoided in patients with COPD with suspected underlying ACO.&#x000a0;</p>
        <p>Regarding LABA/ICS, a&#x000a0;randomized control trial which was published in 2015 showed that after four weeks of once-daily fluticasone furoate/vilanterol therapy, as opposed to a run-in phase of twice-daily fluticasone propionate-salmeterol therapy, 16 patients with ACO experienced a significant improvement in forced expiratory volume in one second (FEV1).<xref ref-type="bibr" rid="article-148550.r25">[25]</xref></p>
        <p>If the patients continue to have symptoms after starting ICS/LABA or ICS/LAMA (Long-acting muscarinic antagonists) therapy, the next step will be to start triple therapy. Adding umeclidinium (LAMA) to fluticasone furoate/vilanterol (ICS/LABA) led to a more significant improvement in FEV1 after four weeks than continuing fluticasone furoate/vilanterol without umeclidinium, according to a randomized, open-label crossover pilot study in 17 patients with ACO.<xref ref-type="bibr" rid="article-148550.r26">[26]</xref></p>
        <p>Another critical pharmacological intervention&#x000a0;for&#x000a0;patients with ACO is biological treatment which has been shown to reduce the exacerbations and use of oral steroids among asthma patients. In one study, the response to treatment with omalizumab was evaluated between individuals with asthma-COPD overlap and asthma patients. They discovered that individuals with severe allergic asthma and overlapping COPD experienced improved asthma control and health-related quality of life after receiving omalizumab medication.<xref ref-type="bibr" rid="article-148550.r16">[16]</xref>&#x000a0;Therefore,&#x000a0;patients with&#x000a0;worsening symptoms or exacerbations despite triple treatment should be examined for signs that might indicate a&#x000a0;response to&#x000a0;the biological asthma medications, such as raised total serum IgE and peripheral blood eosinophilia.&#x000a0;</p>
        <p>Regarding anti-interleukin-5 therapies, phase 2 of a randomized study published recently with benralizumab showed a tendency towards exacerbation reduction in COPD patients with blood eosinophil concentrations of 200 cells per microL or higher. However, the outcomes of two subsequent phase 3 studies in COPD were unfavorable.<xref ref-type="bibr" rid="article-148550.r27">[27]</xref>&#x000a0;Regarding mepolizumab, clinically and statistically significant reductions in moderate or severe exacerbations were shown in a phase 3 study of COPD patients with blood eosinophil levels at or&#x000a0;more than 150 cells/microL at screening or 300 cells/microL in the previous year. However, a parallel study showed negative results.<xref ref-type="bibr" rid="article-148550.r28">[28]</xref>&#x000a0;</p>
        <p>Dupilumab, an anti-IL-4Ra antibody that inhibits both the IL-13 and IL-4 pathways improves lung function and lessens severe asthma attacks. Patients with higher blood eosinophil levels benefit more from this treatment.<xref ref-type="bibr" rid="article-148550.r29">[29]</xref>&#x000a0;For patients with ACO who remain to have symptoms (COPD assessment test-CAT of more than 10 points)&#x000a0;or had recent exacerbation to assess&#x000a0;blood eosinophil levels&#x000a0;and if it is at or&#x000a0;more than 150 cells/microL to increase the dose of inhaled steroid and switch inhaler combination to a different inhaler with higher strength ( such as from&#x000a0;budesonide and formoterol fumarate dihydrate160/4.5 mcg to budesonide/glycopyrrolate/formoterol fumarate 500/50 mcg) and assess clinical response.<xref ref-type="bibr" rid="article-148550.r30">[30]</xref>&#x000a0;</p>
        <p>Macrolides have many applications in chronic obstructive respiratory conditions,&#x000a0;especially with&#x000a0;COPD patients. They have multifaceted therapeutic benefits, including antibacterial, anti-inflammatory, and immunomodulatory effects. A recent Cochrane review found inadequate evidence to support using macrolides in chronic asthma to reduce exacerbations, oral steroid usage, quality of life, or rescue medication use. However, there is relatively little data regarding their use in asthma.<xref ref-type="bibr" rid="article-148550.r31">[31]</xref> Macrolides could be useful in ACO patients with recurrent exacerbations and non-eosinophilic characteristics, but further investigation is required before drawing firm conclusions.</p>
      </sec>
      <sec id="article-148550.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Other chronic airway diseases that can mimic ACO are congestive heart failure, bronchiectasis, and&#x000a0;bronchiolitis obliterans are included in the differential diagnosis of ACO.&#x000a0;</p>
        <p>Wheezing is a symptom of congestive heart failure (CHF), which is sometimes challenging to distinguish from ACO. The diagnosis of CHF can be made based on a history of orthopnea and paroxysmal nocturnal dyspnea, fine basal crackles on chest auscultation, and characteristic features on chest radiography.<xref ref-type="bibr" rid="article-148550.r32">[32]</xref>&#x000a0;</p>
        <p>Other conditions like bronchiectasis can present as ACO. However, the physical examination of bronchiectasis patients reveals coarse crackles and potentially clubbing in addition to aberrant findings on computed tomography (CT) scans and chest radiography.<xref ref-type="bibr" rid="article-148550.r33">[33]</xref>&#x000a0;</p>
        <p>Bronchiolitis obliterans&#x000a0;is most frequently observed after viral infection, bone marrow transplantation, or associated with connective tissue diseases.&#x000a0;CT scan findings often include tree-in-bud nodularity and a mosaic pattern&#x000a0;of lung parenchyma.<xref ref-type="bibr" rid="article-148550.r34">[34]</xref></p>
      </sec>
      <sec id="article-148550.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>ACO is associated with&#x000a0;more severe symptoms, reduced quality of life, and&#x000a0;more frequent exacerbations. Also, It&#x000a0;is associated with&#x000a0;a rapid decrease in lung function.<xref ref-type="bibr" rid="article-148550.r1">[1]</xref>&#x000a0;In one study, the authors reported that patients with ACO&#x000a0;are more likely to experience frequent and severe exacerbations than patients with COPD. It also showed that they have more hospitalization.<xref ref-type="bibr" rid="article-148550.r35">[35]</xref>&#x000a0;</p>
        <p>Moreover, as individuals with frequent exacerbations experience a higher loss of lung function, a reduced FEV1 is linked to worsening disease severity, especially concerning people with ACO.<xref ref-type="bibr" rid="article-148550.r36">[36]</xref>&#x000a0;According to another study's findings, persistent asthma&#x000a0;with chronic airflow restriction&#x000a0;has&#x000a0;a higher&#x000a0;mortality rate.<xref ref-type="bibr" rid="article-148550.r37">[37]</xref></p>
      </sec>
      <sec id="article-148550.s11" sec-type="Complications">
        <title>Complications</title>
        <p>ACO complications are not different from COPD and asthma complications, including recurrent respiratory infections like pneumonia, pneumothorax, hypoxia, and cardiovascular events. Regarding pneumonia, the studies showed an increased risk of exacerbation among ACO patients compared with patients with COPD. This leads to increased hospitalizations.<xref ref-type="bibr" rid="article-148550.r35">[35]</xref>&#x000a0;Also, cardiovascular complications such as pulmonary hypertension should be ruled out if the patient does not improve on the treatment.</p>
      </sec>
      <sec id="article-148550.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>ACO is a lung condition that makes breathing difficult. It has both asthma and COPD features. It mostly happens due to having risk factors for both asthma and COPD. The airways, the branching tubes that carry air through the lungs, can become congested with mucus and narrow in people with ACO. Also susceptible to damage are the air sacs. People feel exhausted and out of breath as a result. The main difference in symptoms between ACO and COPD and asthma is that the patient with ACO has more rate of exacerbations than patients with asthma or COPD alone. As a patient, to avoid developing COPD, you have to avoid risk factors that can lead to the development of the disease or exacerbations.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Avoid smoking. The most important&#x000a0;measure patients can do for their&#x000a0;health is to stop smoking. If&#x000a0;they have other underlying risk factors for asthma, smoking can lead to ACO development and makes symptoms more severe.&#x000a0;Clinicians may need to assist with smoking cessation.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Reduce&#x000a0;the patient's risk of infection because some infections can exacerbate ACO symptoms. By receiving specific vaccinations,&#x000a0;patients can reduce their&#x000a0;risk. These include receiving an annual flu shot, the pneumococcal vaccine, and subsequent doses of the COVID-19 vaccine.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Avoid triggers, such as dust or pollution, that worsen a patient's breathing.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-148550.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>This&#x000a0;activity discusses why&#x000a0;ACO diagnosis and management are challenging to healthcare providers, as there are no specific guidelines for diagnosis. The disease is underdiagnosed and not adequately managed. Strategies exist that&#x000a0;can prevent leaving patients with ACO undiagnosed and untreated. Therefore, an interprofessional healthcare team approach is crucial to proper patient management. Family clinicians should consult a pulmonologist to evaluate&#x000a0;the patient more thoroughly.&#x000a0;Clinicians should routinely check COPD patients for eosinophilia and ask them about other symptoms associated with asthma and ACO.</p>
        <p>Respiratory therapists are essential team members and will often perform lung function tests and respiratory therapies. Nurses&#x000a0;may assist in the patient workup, counsel on the condition, and help coordinate the activities of various team members. Collaboration with clinical pharmacists is essential. They can teach patients the proper inhaler techniques and increase compliance, answer patient questions about their medication regimen, and perform medication reconciliation. All team members should report any findings, new symptoms, or concerns to the clinicians and the rest of the team for further evaluation and possible corrective action.</p>
        <p>These examples of interprofessional care highlight how this model can drive improved patient outcomes. [Level 5]</p>
      </sec>
      <sec id="article-148550.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=148550&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=148550">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/lung-disease-respiratory-health/asthma-and-copd-overlap/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=148550">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/148550/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=148550">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-148550.s15">
        <title>References</title>
        <ref id="article-148550.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gibson</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Simpson</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>The overlap syndrome of asthma and COPD: what are its features and how important is it?</article-title>
            <source>Thorax</source>
            <year>2009</year>
            <month>Aug</month>
            <volume>64</volume>
            <issue>8</issue>
            <fpage>728</fpage>
            <page-range>728-35</page-range>
            <pub-id pub-id-type="pmid">19638566</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148550.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fouka</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Papaioannou</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Hillas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Steiropoulos</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Asthma-COPD Overlap Syndrome: Recent Insights and Unanswered Questions.</article-title>
            <source>J Pers Med</source>
            <year>2022</year>
            <month>Apr</month>
            <day>28</day>
            <volume>12</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">35629128</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148550.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leung</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Sin</surname>
                <given-names>DD</given-names>
              </name>
            </person-group>
            <article-title>Asthma-COPD overlap syndrome: pathogenesis, clinical features, and therapeutic targets.</article-title>
            <source>BMJ</source>
            <year>2017</year>
            <month>Sep</month>
            <day>25</day>
            <volume>358</volume>
            <fpage>j3772</fpage>
            <pub-id pub-id-type="pmid">28947632</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148550.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>L&#x000f8;kke</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lange</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Scharling</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fabricius</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vestbo</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Developing COPD: a 25 year follow up study of the general population.</article-title>
            <source>Thorax</source>
            <year>2006</year>
            <month>Nov</month>
            <volume>61</volume>
            <issue>11</issue>
            <fpage>935</fpage>
            <page-range>935-9</page-range>
            <pub-id pub-id-type="pmid">17071833</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148550.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brutsche</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Downs</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Schindler</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gerbase</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Frey</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Russi</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Ackermann-Liebrich</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Leuenberger</surname>
                <given-names>P</given-names>
              </name>
              <collab>SAPALDIA Team</collab>
            </person-group>
            <article-title>Bronchial hyperresponsiveness and the development of asthma and COPD in asymptomatic individuals: SAPALDIA cohort study.</article-title>
            <source>Thorax</source>
            <year>2006</year>
            <month>Aug</month>
            <volume>61</volume>
            <issue>8</issue>
            <fpage>671</fpage>
            <page-range>671-7</page-range>
            <pub-id pub-id-type="pmid">16670173</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148550.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gottlieb</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Sparrow</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>O'Connor</surname>
                <given-names>GT</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>ST</given-names>
              </name>
            </person-group>
            <article-title>Skin test reactivity to common aeroallergens and decline of lung function. The Normative Aging Study.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>1996</year>
            <month>Feb</month>
            <volume>153</volume>
            <issue>2</issue>
            <fpage>561</fpage>
            <page-range>561-6</page-range>
            <pub-id pub-id-type="pmid">8564098</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148550.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ding</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>DiBonaventura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Karlsson</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ling</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Asthma-chronic obstructive pulmonary disease overlap syndrome in the urban Chinese population: prevalence and disease burden using the 2010, 2012, and 2013 China National Health and Wellness Surveys.</article-title>
            <source>Int J Chron Obstruct Pulmon Dis</source>
            <year>2016</year>
            <volume>11</volume>
            <fpage>1139</fpage>
            <page-range>1139-50</page-range>
            <pub-id pub-id-type="pmid">27354777</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148550.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wheaton</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Pleasants</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Croft</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Ohar</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Heidari</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mannino</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Strange</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Gender and asthma-chronic obstructive pulmonary disease overlap syndrome.</article-title>
            <source>J Asthma</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>53</volume>
            <issue>7</issue>
            <fpage>720</fpage>
            <page-range>720-31</page-range>
            <pub-id pub-id-type="pmid">27043854</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148550.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alshabanat</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zafari</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Albanyan</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Dairi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>FitzGerald</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Asthma and COPD Overlap Syndrome (ACOS): A Systematic Review and Meta Analysis.</article-title>
            <source>PLoS One</source>
            <year>2015</year>
            <volume>10</volume>
            <issue>9</issue>
            <fpage>e0136065</fpage>
            <pub-id pub-id-type="pmid">26336076</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148550.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chung</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Kong</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Ryu</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Characteristics and self-rated health of overlap syndrome.</article-title>
            <source>Int J Chron Obstruct Pulmon Dis</source>
            <year>2014</year>
            <volume>9</volume>
            <fpage>795</fpage>
            <page-range>795-804</page-range>
            <pub-id pub-id-type="pmid">25092973</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148550.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kumbhare</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pleasants</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ohar</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Strange</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Characteristics and Prevalence of Asthma/Chronic Obstructive Pulmonary Disease Overlap in the United States.</article-title>
            <source>Ann Am Thorac Soc</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>13</volume>
            <issue>6</issue>
            <fpage>803</fpage>
            <page-range>803-10</page-range>
            <pub-id pub-id-type="pmid">26974689</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148550.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hardin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Silverman</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Barr</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Hansel</surname>
                <given-names>NN</given-names>
              </name>
              <name>
                <surname>Schroeder</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Make</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Crapo</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Hersh</surname>
                <given-names>CP</given-names>
              </name>
              <collab>COPDGene Investigators</collab>
            </person-group>
            <article-title>The clinical features of the overlap between COPD and asthma.</article-title>
            <source>Respir Res</source>
            <year>2011</year>
            <month>Sep</month>
            <day>27</day>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>127</fpage>
            <pub-id pub-id-type="pmid">21951550</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148550.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vaz Fragoso</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Agogo</surname>
                <given-names>GO</given-names>
              </name>
              <name>
                <surname>Allore</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>McAvay</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>Asthma-COPD overlap syndrome in the US: a prospective population-based analysis of patient-reported outcomes and health care utilization.</article-title>
            <source>Int J Chron Obstruct Pulmon Dis</source>
            <year>2017</year>
            <volume>12</volume>
            <fpage>517</fpage>
            <page-range>517-527</page-range>
            <pub-id pub-id-type="pmid">28223792</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148550.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hikichi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hashimoto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gon</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Asthma and COPD overlap pathophysiology of ACO.</article-title>
            <source>Allergol Int</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>67</volume>
            <issue>2</issue>
            <fpage>179</fpage>
            <page-range>179-186</page-range>
            <pub-id pub-id-type="pmid">29550368</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148550.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chung</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Kao</surname>
                <given-names>CH</given-names>
              </name>
            </person-group>
            <article-title>Comparison of acute respiratory events between asthma-COPD overlap syndrome and COPD patients: a population-based cohort study.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2015</year>
            <month>May</month>
            <volume>94</volume>
            <issue>17</issue>
            <fpage>e755</fpage>
            <pub-id pub-id-type="pmid">25929911</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148550.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Venkata</surname>
                <given-names>AN</given-names>
              </name>
            </person-group>
            <article-title>Asthma-COPD overlap: review of diagnosis and management.</article-title>
            <source>Curr Opin Pulm Med</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>26</volume>
            <issue>2</issue>
            <fpage>155</fpage>
            <page-range>155-161</page-range>
            <pub-id pub-id-type="pmid">31714273</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148550.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stanojevic</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kaminsky</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Aliverti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barjaktarevic</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Culver</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Derom</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Hallstrand</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Leuppi</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>MacIntyre</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>McCormack</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rosenfeld</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Swenson</surname>
                <given-names>ER</given-names>
              </name>
            </person-group>
            <article-title>ERS/ATS technical standard on interpretive strategies for routine lung function tests.</article-title>
            <source>Eur Respir J</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>60</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">34949706</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148550.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sin</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Miravitlles</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mannino</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Soriano</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Celli</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Nakano</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Wark</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Wechsler</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>What is asthma-COPD overlap syndrome? Towards a consensus definition from a round table discussion.</article-title>
            <source>Eur Respir J</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>48</volume>
            <issue>3</issue>
            <fpage>664</fpage>
            <page-range>664-73</page-range>
            <pub-id pub-id-type="pmid">27338195</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148550.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anthonisen</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Connett</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>RP</given-names>
              </name>
            </person-group>
            <article-title>Smoking and lung function of Lung Health Study participants after 11 years.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2002</year>
            <month>Sep</month>
            <day>01</day>
            <volume>166</volume>
            <issue>5</issue>
            <fpage>675</fpage>
            <page-range>675-9</page-range>
            <pub-id pub-id-type="pmid">12204864</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148550.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Freiler</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>The Asthma-COPD Overlap Syndrome.</article-title>
            <source>Fed Pract</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>32</volume>
            <issue>Suppl 10</issue>
            <fpage>19S</fpage>
            <page-range>19S-23S</page-range>
            <pub-id pub-id-type="pmid">30766096</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148550.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salpeter</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Buckley</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Ormiston</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Salpeter</surname>
                <given-names>EE</given-names>
              </name>
            </person-group>
            <article-title>Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths.</article-title>
            <source>Ann Intern Med</source>
            <year>2006</year>
            <month>Jun</month>
            <day>20</day>
            <volume>144</volume>
            <issue>12</issue>
            <fpage>904</fpage>
            <page-range>904-12</page-range>
            <pub-id pub-id-type="pmid">16754916</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148550.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pascoe</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Barnes</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Brusselle</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Compton</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Criner</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Dransfield</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Halpin</surname>
                <given-names>DMG</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Hartley</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lange</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lettis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lipson</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Lomas</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Martinez</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Papi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Roche</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>van der Valk</surname>
                <given-names>RJP</given-names>
              </name>
              <name>
                <surname>Wise</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial.</article-title>
            <source>Lancet Respir Med</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>7</volume>
            <issue>9</issue>
            <fpage>745</fpage>
            <page-range>745-756</page-range>
            <pub-id pub-id-type="pmid">31281061</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148550.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bafadhel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>De Blas</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Calverley</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Rennard</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Richter</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fager&#x000e5;s</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials.</article-title>
            <source>Lancet Respir Med</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>117</fpage>
            <page-range>117-126</page-range>
            <pub-id pub-id-type="pmid">29331313</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148550.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nelson</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Bleecker</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Yancey</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Dorinsky</surname>
                <given-names>PM</given-names>
              </name>
              <collab>SMART Study Group</collab>
            </person-group>
            <article-title>The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol.</article-title>
            <source>Chest</source>
            <year>2006</year>
            <month>Jan</month>
            <volume>129</volume>
            <issue>1</issue>
            <fpage>15</fpage>
            <page-range>15-26</page-range>
            <pub-id pub-id-type="pmid">16424409</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148550.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ishiura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Fujimura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shiba</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ohkura</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hara</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kasahara</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>A comparison of the efficacy of once-daily fluticasone furoate/vilanterole with twice-daily fluticasone propionate/salmeterol in asthma-COPD overlap syndrome.</article-title>
            <source>Pulm Pharmacol Ther</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>35</volume>
            <fpage>28</fpage>
            <page-range>28-33</page-range>
            <pub-id pub-id-type="pmid">26497109</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148550.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ishiura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Fujimura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ohkura</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hara</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kasahara</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ishii</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tamaki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shimizu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nomura</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Effect of triple therapy in patients with asthma-COPD overlap&#x02029;.</article-title>
            <source>Int J Clin Pharmacol Ther</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>57</volume>
            <issue>8</issue>
            <fpage>384</fpage>
            <page-range>384-392</page-range>
            <pub-id pub-id-type="pmid">31232275</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148550.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brightling</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Bleecker</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Panettieri</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Bafadhel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>She</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Birrell</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>van der Merwe</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study.</article-title>
            <source>Lancet Respir Med</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>2</volume>
            <issue>11</issue>
            <fpage>891</fpage>
            <page-range>891-901</page-range>
            <pub-id pub-id-type="pmid">25208464</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148550.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pavord</surname>
                <given-names>ID</given-names>
              </name>
              <name>
                <surname>Chanez</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Criner</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Kerstjens</surname>
                <given-names>HAM</given-names>
              </name>
              <name>
                <surname>Korn</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lugogo</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Martinot</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Sagara</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Albers</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Bradford</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Yancey</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Sciurba</surname>
                <given-names>FC</given-names>
              </name>
            </person-group>
            <article-title>Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease.</article-title>
            <source>N Engl J Med</source>
            <year>2017</year>
            <month>Oct</month>
            <day>26</day>
            <volume>377</volume>
            <issue>17</issue>
            <fpage>1613</fpage>
            <page-range>1613-1629</page-range>
            <pub-id pub-id-type="pmid">28893134</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148550.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rabe</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Nair</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Brusselle</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Maspero</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Castro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sher</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hamilton</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Swanson</surname>
                <given-names>BN</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Staudinger</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Pirozzi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Antoni</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Amin</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ruddy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Akinlade</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>NMH</given-names>
              </name>
              <name>
                <surname>Stahl</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yancopoulos</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Teper</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma.</article-title>
            <source>N Engl J Med</source>
            <year>2018</year>
            <month>Jun</month>
            <day>28</day>
            <volume>378</volume>
            <issue>26</issue>
            <fpage>2475</fpage>
            <page-range>2475-2485</page-range>
            <pub-id pub-id-type="pmid">29782224</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148550.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jones</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Harding</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Berry</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wiklund</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Kline Leidy</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Development and first validation of the COPD Assessment Test.</article-title>
            <source>Eur Respir J</source>
            <year>2009</year>
            <month>Sep</month>
            <volume>34</volume>
            <issue>3</issue>
            <fpage>648</fpage>
            <page-range>648-54</page-range>
            <pub-id pub-id-type="pmid">19720809</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148550.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Undela</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Goldsmith</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kew</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Ferrara</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Macrolides versus placebo for chronic asthma.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2021</year>
            <month>Nov</month>
            <day>22</day>
            <volume>11</volume>
            <issue>11</issue>
            <fpage>CD002997</fpage>
            <pub-id pub-id-type="pmid">34807989</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148550.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mosenifar</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Differentiating COPD from asthma in clinical practice.</article-title>
            <source>J Intensive Care Med</source>
            <year>2007</year>
            <season>Sep-Oct</season>
            <volume>22</volume>
            <issue>5</issue>
            <fpage>300</fpage>
            <page-range>300-9</page-range>
            <pub-id pub-id-type="pmid">17895488</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148550.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hill</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Chalmers</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>De Soyza</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Elborn</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Floto</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Grillo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gruffydd-Jones</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Harvey</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Haworth</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Hiscocks</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hurst</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kelleher</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Bedi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Payne</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Saleh</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Screaton</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tunney</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Whitters</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Loebinger</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>British Thoracic Society Guideline for bronchiectasis in adults.</article-title>
            <source>Thorax</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>74</volume>
            <issue>Suppl 1</issue>
            <fpage>1</fpage>
            <page-range>1-69</page-range>
            <pub-id pub-id-type="pmid">30545985</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148550.r34">
          <label>34</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Krishna</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Anjum</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Oliver</surname>
                <given-names>TI</given-names>
              </name>
            </person-group>
            <chapter-title>Bronchiolitis Obliterans</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>14</day>
            <pub-id pub-id-type="pmid">28722895</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148550.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Menezes</surname>
                <given-names>AMB</given-names>
              </name>
              <name>
                <surname>Montes de Oca</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>P&#x000e9;rez-Padilla</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nadeau</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wehrmeister</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Lopez-Varela</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Mui&#x000f1;o</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jardim</surname>
                <given-names>JRB</given-names>
              </name>
              <name>
                <surname>Valdivia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>T&#x000e1;lamo</surname>
                <given-names>C</given-names>
              </name>
              <collab>PLATINO Team</collab>
            </person-group>
            <article-title>Increased risk of exacerbation and hospitalization in subjects with an overlap phenotype: COPD-asthma.</article-title>
            <source>Chest</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>145</volume>
            <issue>2</issue>
            <fpage>297</fpage>
            <page-range>297-304</page-range>
            <pub-id pub-id-type="pmid">24114498</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148550.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gibson</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>McDonald</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Granchelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Olin</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>Asthma and Comorbid Conditions-Pulmonary Comorbidity.</article-title>
            <source>J Allergy Clin Immunol Pract</source>
            <year>2021</year>
            <month>Nov</month>
            <volume>9</volume>
            <issue>11</issue>
            <fpage>3868</fpage>
            <page-range>3868-3875</page-range>
            <pub-id pub-id-type="pmid">34492401</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148550.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Panizza</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>de Klerk</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Finucane</surname>
                <given-names>KE</given-names>
              </name>
            </person-group>
            <article-title>Mortality and airflow obstruction in asthma: a 17-year follow-up study.</article-title>
            <source>Intern Med J</source>
            <year>2006</year>
            <month>Dec</month>
            <volume>36</volume>
            <issue>12</issue>
            <fpage>773</fpage>
            <page-range>773-80</page-range>
            <pub-id pub-id-type="pmid">17096740</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
